Logo image of KPTI

KARYOPHARM THERAPEUTICS INC (KPTI) Stock Fundamental Analysis

USA - NASDAQ:KPTI - US48576U2050 - Common Stock

5.8 USD
-0.16 (-2.68%)
Last: 10/31/2025, 8:00:02 PM
6 USD
+0.2 (+3.45%)
After Hours: 10/31/2025, 8:00:02 PM
Fundamental Rating

1

Overall KPTI gets a fundamental rating of 1 out of 10. We evaluated KPTI against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of KPTI have multiple concerns. KPTI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KPTI has reported negative net income.
In the past year KPTI has reported a negative cash flow from operations.
In the past 5 years KPTI always reported negative net income.
KPTI had a negative operating cash flow in each of the past 5 years.
KPTI Yearly Net Income VS EBIT VS OCF VS FCFKPTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

KPTI has a worse Return On Assets (-117.82%) than 78.84% of its industry peers.
Industry RankSector Rank
ROA -117.82%
ROE N/A
ROIC N/A
ROA(3y)-50.71%
ROA(5y)-51.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KPTI Yearly ROA, ROE, ROICKPTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600 800

1.3 Margins

KPTI has a Gross Margin of 96.37%. This is amongst the best in the industry. KPTI outperforms 95.88% of its industry peers.
KPTI's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for KPTI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.86%
GM growth 5Y0.37%
KPTI Yearly Profit, Operating, Gross MarginsKPTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

0

2. Health

2.1 Basic Checks

KPTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
KPTI has more shares outstanding than it did 1 year ago.
KPTI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, KPTI has a worse debt to assets ratio.
KPTI Yearly Shares OutstandingKPTI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
KPTI Yearly Total Debt VS Total AssetsKPTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -23.85, we must say that KPTI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of KPTI (-23.85) is worse than 86.52% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -23.85
ROIC/WACCN/A
WACC7.49%
KPTI Yearly LT Debt VS Equity VS FCFKPTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 0.99 indicates that KPTI may have some problems paying its short term obligations.
KPTI has a worse Current ratio (0.99) than 87.27% of its industry peers.
A Quick Ratio of 0.94 indicates that KPTI may have some problems paying its short term obligations.
KPTI has a worse Quick ratio (0.94) than 87.45% of its industry peers.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.94
KPTI Yearly Current Assets VS Current LiabilitesKPTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for KPTI have decreased strongly by -17.19% in the last year.
The Revenue has decreased by -5.76% in the past year.
Measured over the past years, KPTI shows a very strong growth in Revenue. The Revenue has been growing by 28.85% on average per year.
EPS 1Y (TTM)-17.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-292%
Revenue 1Y (TTM)-5.76%
Revenue growth 3Y-11.54%
Revenue growth 5Y28.85%
Sales Q2Q%-11.35%

3.2 Future

The Earnings Per Share is expected to grow by 15.22% on average over the next years. This is quite good.
The Revenue is expected to grow by 23.98% on average over the next years. This is a very strong growth
EPS Next Y-12.48%
EPS Next 2Y19.68%
EPS Next 3Y19.63%
EPS Next 5Y15.22%
Revenue Next Year-0.16%
Revenue Next 2Y4.41%
Revenue Next 3Y13.18%
Revenue Next 5Y23.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
KPTI Yearly Revenue VS EstimatesKPTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
KPTI Yearly EPS VS EstimatesKPTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KPTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KPTI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KPTI Price Earnings VS Forward Price EarningsKPTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KPTI Per share dataKPTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

KPTI's earnings are expected to grow with 19.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.68%
EPS Next 3Y19.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KPTI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KARYOPHARM THERAPEUTICS INC

NASDAQ:KPTI (10/31/2025, 8:00:02 PM)

After market: 6 +0.2 (+3.45%)

5.8

-0.16 (-2.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners51.13%
Inst Owner Change0.33%
Ins Owners1.14%
Ins Owner Change1.43%
Market Cap92.39M
Revenue(TTM)137.27M
Net Income(TTM)-123566000
Analysts80
Price Target15.98 (175.52%)
Short Float %9.55%
Short Ratio6.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.85%
Min EPS beat(2)-3.34%
Max EPS beat(2)35.04%
EPS beat(4)3
Avg EPS beat(4)11.18%
Min EPS beat(4)-3.34%
Max EPS beat(4)35.04%
EPS beat(8)5
Avg EPS beat(8)22.63%
EPS beat(12)8
Avg EPS beat(12)18.39%
EPS beat(16)11
Avg EPS beat(16)26.83%
Revenue beat(2)1
Avg Revenue beat(2)-7.91%
Min Revenue beat(2)-16.5%
Max Revenue beat(2)0.68%
Revenue beat(4)2
Avg Revenue beat(4)-7.33%
Min Revenue beat(4)-16.5%
Max Revenue beat(4)0.68%
Revenue beat(8)3
Avg Revenue beat(8)-3.88%
Revenue beat(12)6
Avg Revenue beat(12)-2.41%
Revenue beat(16)10
Avg Revenue beat(16)16.85%
PT rev (1m)-10.98%
PT rev (3m)-52.63%
EPS NQ rev (1m)4.81%
EPS NQ rev (3m)8.96%
EPS NY rev (1m)-1.11%
EPS NY rev (3m)9.04%
Revenue NQ rev (1m)5.18%
Revenue NQ rev (3m)6.74%
Revenue NY rev (1m)1.43%
Revenue NY rev (3m)2.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.67
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.59
EYN/A
EPS(NY)-5.71
Fwd EYN/A
FCF(TTM)-6.46
FCFYN/A
OCF(TTM)-6.46
OCFYN/A
SpS8.62
BVpS-15
TBVpS-15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -117.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.37%
FCFM N/A
ROA(3y)-50.71%
ROA(5y)-51.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.86%
GM growth 5Y0.37%
F-Score3
Asset Turnover1.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.56%
Cap/Sales 0.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.99
Quick Ratio 0.94
Altman-Z -23.85
F-Score3
WACC7.49%
ROIC/WACCN/A
Cap/Depr(3y)20.37%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-292%
EPS Next Y-12.48%
EPS Next 2Y19.68%
EPS Next 3Y19.63%
EPS Next 5Y15.22%
Revenue 1Y (TTM)-5.76%
Revenue growth 3Y-11.54%
Revenue growth 5Y28.85%
Sales Q2Q%-11.35%
Revenue Next Year-0.16%
Revenue Next 2Y4.41%
Revenue Next 3Y13.18%
Revenue Next 5Y23.98%
EBIT growth 1Y12.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.18%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.13%
OCF growth 3YN/A
OCF growth 5YN/A

KARYOPHARM THERAPEUTICS INC / KPTI FAQ

Can you provide the ChartMill fundamental rating for KARYOPHARM THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to KPTI.


What is the valuation status of KARYOPHARM THERAPEUTICS INC (KPTI) stock?

ChartMill assigns a valuation rating of 0 / 10 to KARYOPHARM THERAPEUTICS INC (KPTI). This can be considered as Overvalued.


How profitable is KARYOPHARM THERAPEUTICS INC (KPTI) stock?

KARYOPHARM THERAPEUTICS INC (KPTI) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for KPTI stock?

The Earnings per Share (EPS) of KARYOPHARM THERAPEUTICS INC (KPTI) is expected to decline by -12.48% in the next year.